Phaseline

Companies › Shanghai Argo Biopharmaceutical

Shanghai Argo Biopharmaceutical: clinical trials, targets and expected readouts

6 active drug programs in 7 registered trials: 4 Phase 1, 3 Phase 2; Other, Infectious disease, Cardiovascular, Immunology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
BW-00112–Phase 2Mixed DyslipidemiaMar 2028
BW-20805–Phase 2Hereditary Angioedema (HAE)Mar 2028
BW-20507–Phase 2Chronic Hepatitis BMay 2028
BW-40202
conjugate drug
–Phase 1Healthy Volunteers OnlyDec 2026
BW-50218 Injection–Phase 1Healthy Participants StudyJun 2027
BW-41012 injection–Phase 1HVOct 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06917482BW-40202Phase 1Healthy Volunteers OnlyOtherDec 2026
NCT07577479BW-50218 InjectionPhase 1Healthy Participants StudyOtherJun 2027
NCT07401472BW-50218 InjectionPhase 1Healthy Participants StudyOtherJun 2027
NCT07584876BW-41012 injectionPhase 1HVOtherOct 2027
NCT06497127BW-00112Phase 2Mixed DyslipidemiaCardiovascularMar 2028
NCT06846398BW-20805Phase 2Hereditary Angioedema (HAE)ImmunologyMar 2028
NCT07135349BW-20507Phase 2Chronic Hepatitis BInfectious diseaseMay 2028

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Tortugas Neuroscience Basilea Pharmaceutica Mirador Therapeutics Sirnaomics Shanghai Ark Biopharmaceutical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.